US4673667A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Lipids with plasmin inhibitory properties
Assignee: Boston University
•
Filing: 1985-10-31
•
Granted: 1987-06-16
•
Expires: 2005-10-31
Abstract
Abstract Plasmin inhibitory substances have been found in mammalian omental extracts. The substances all contain lipid components. In addition, related commercially available lipid containing molecules, such as mono-, di-, and trisialogangliosides are found to fossess unexpected plasmin inhibitory properties. This suggests methods of therapy for diseases and conditions where blood clotting and fibrin degradation products, are implicated.
Inventors
- 👤 Nicholas Catsimpoolas
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 17:20
CPC Classifications
C; C07; C07H; C07H15/00; C07H15/02; C07H15/04; C07H15/10; A; A61; A61K; A61K31/00; A61K31/70
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
47 words
A method of treating conditions characterized by excess plasmin activity comprising administering an effective amount of a pharmaceutically acceptable plasmin inhibiting ganglioside to a subject with a condition characterized by excess plasmin activity under conditions favoring inhibition of plasmin activity by said plasmin inhibiting ganglioside containing molecule.
Claim 2
Independent Claim
47 words
A method of treating conditions characterized by excess plasmin activity comprising administering an effective amount of a pharmaceutically acceptable plasmin inhibiting ganglioside to a subject with a condition characterized by excess plasmin activity under conditions favoring inhibition of plasmin activity by said plasmin inhibiting ganglioside containing molecule.
Claim 3
Dependent Claim
12 words
A method as in claim 1, wherein said ganglioside is a trisialoganglioside.
Claim 4
Dependent Claim
15 words
A method as in claim 1, wherein said ganglioside is administered to a human being.
Claim 5
Dependent Claim
19 words
A method as in claim 1, wherein said condition is characterized by vascular-endothelial damage, hypoxemia, tachiphea, or vascular injury.
Claim 6
Dependent Claim
18 words
A method as in claim 1 wherein said condition is characterized by excessive fibrin or fibrin degradation products.
Claim 7
Dependent Claim
18 words
A method as in claim 1, wherein said ganglioside is administered in intravenous, intramuscular, topical, or oral form.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-06-15 | 1990-12-15 | 1991-06-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-06-15 | 1994-12-15 | 1995-06-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-06-15 | 1998-12-15 | 1999-06-16 | $7700.00 | Window Closed / Lapsed |